These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 8230817)

  • 1. [Accumulation of a disopyramide metabolite in renal failure].
    Otsu T; Ito T; Inagaki Y; Amano I; Masamoto S; Niwa M
    Nihon Jinzo Gakkai Shi; 1993 Sep; 35(9):1065-71. PubMed ID: 8230817
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Accumulation of a disopyramide metabolite in renal failure.
    Inagaki Y; Amano I; Otsu T
    ASAIO J; 1993; 39(3):M609-13. PubMed ID: 8268610
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Relationship between alpha 1-acid glycoprotein and distribution of disopyramide and mono-N-dealkyldisopyramide in whole blood.
    Bredesen JE; Kierulf P
    Br J Clin Pharmacol; 1986 Sep; 22(3):281-6. PubMed ID: 3768240
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Relationship between alpha 1-acid glycoprotein and plasma binding of disopyramide and mono-N-dealkyldisopyramide.
    Bredesen JE; Kierulf P
    Br J Clin Pharmacol; 1984 Nov; 18(5):779-84. PubMed ID: 6508986
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relationship between the therapeutic effects or side-effects and the serum disopyramide or mono-N-dealkylated disopyramide concentration after repeated oral administration of disopyramide to arrhythmic patients.
    Masuhara K; Ohno T; Hamaguchi K; Katoh K; Kashiwada K; Takahashi S; Tanaka Y; Someya K; Ogata H
    Int J Clin Pharmacol Res; 1995; 15(3):103-13. PubMed ID: 8847151
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of serum concentrations of disopyramide and its metabolite mono-N-dealkyldisopyramide on the anticholinergic side effects associated with disopyramide.
    Tsuchishita Y; Fukumoto K; Kusumoto M; Ueno K
    Biol Pharm Bull; 2008 Jul; 31(7):1368-70. PubMed ID: 18591776
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Stereoselective metabolism and pharmacokinetics of disopyramide enantiomers in humans.
    Le Corre P; Gibassier D; Sado P; Le Verge R
    Drug Metab Dispos; 1988; 16(6):858-64. PubMed ID: 2907466
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Plasma binding of disopyramide and mono-N-dealkyldisopyramide.
    Bredesen JE; Pike E; Lunde PK
    Br J Clin Pharmacol; 1982 Nov; 14(5):673-6. PubMed ID: 7138747
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Frequency and voltage-dependent effects of mono-N-dealkyldisopyramide, the major metabolite of disopyramide, in canine ventricular tissue.
    Toy W; Sasyniuk BI
    J Pharmacol Exp Ther; 1990 Aug; 254(2):603-11. PubMed ID: 2166798
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics and optimum dose of disopyramide in patients with chronic renal failure.
    Nagura Y; Kuno T; Yanai M; Maejima M; Okada K; Maeda H; Inoue M; Takahashi S; Hatano M
    Nihon Jinzo Gakkai Shi; 1991 May; 33(5):539-43. PubMed ID: 1895553
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The pharmacokinetics of disopyramide and mono-N-dealkyl-disopyramide in humans.
    Aitio ML; Allonen H; Kanto J; Mäntylä R
    Int J Clin Pharmacol Ther Toxicol; 1982 May; 20(5):219-26. PubMed ID: 7095921
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [The treatment of hyperhomocysteinemia in patients on dialysis: folic acid or the high-flow polysulphonic membrane?].
    Lovcić V; Kes P; Zeljko R; Kusec V
    Acta Med Croatica; 2006 Jun; 60(3):201-8. PubMed ID: 16933832
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Accumulation of vitamin E metabolites in the blood of renal failure patients.
    Galli F; Floridi AG; Floridi A; Buoncristiani U
    Clin Nutr; 2004 Apr; 23(2):205-12. PubMed ID: 15030960
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A potent inhibitory effect of erythromycin and other macrolide antibiotics on the mono-N-dealkylation metabolism of disopyramide with human liver microsomes.
    Echizen H; Kawasaki H; Chiba K; Tani M; Ishizaki T
    J Pharmacol Exp Ther; 1993 Mar; 264(3):1425-31. PubMed ID: 8450476
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Stereoselective disposition and metabolism of disopyramide in pediatric patients.
    Echizen H; Takahashi H; Nakamura H; Ochiai K; Chiba K; Koike K; Ogata H; Ishizaki T
    J Pharmacol Exp Ther; 1991 Dec; 259(3):953-60. PubMed ID: 1762088
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Stereoselective biliary elimination of disopyramide and mono-N-desisopropyldisopyramide in humans.
    le Corre P; Malledant Y; Chevanne F; Sado P; le Verge R
    Chirality; 1992; 4(2):80-3. PubMed ID: 1616827
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A simple method for the simulation of unbound serum disopyramide concentration in patients.
    Kishino S; Kohri N; Iseki K; Miyazaki K; Nomura A; Yasuda H
    J Pharmacobiodyn; 1991 Sep; 14(9):493-9. PubMed ID: 1779403
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics of disopyramide in the dog. Importance of mono-N-dealkylated metabolite kinetics in assessing pharmacokinetic modeling of the parent drug.
    Cook CS; Gwilt PR; Kowalski K; Gupta S; Oppermann J; Karim A
    Drug Metab Dispos; 1990; 18(1):42-9. PubMed ID: 1970776
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Glucose-added dialysis fluid prevents asymptomatic hypoglycaemia in regular haemodialysis.
    Burmeister JE; Scapini A; da Rosa Miltersteiner D; da Costa MG; Campos BM
    Nephrol Dial Transplant; 2007 Apr; 22(4):1184-9. PubMed ID: 17272314
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of combination therapy with peritoneal dialysis and hemodialysis on peritoneal function.
    Moriishi M; Kawanishi H; Tsuchiya S
    Adv Perit Dial; 2010; 26():67-70. PubMed ID: 21348383
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.